Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02WFK
|
|||
| Former ID |
DAP001335
|
|||
| Drug Name |
Cycloserine
|
|||
| Synonyms |
D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
| Tuberculosis [ICD-11: 1B10-1B14] | Approved | [2], [3] | ||
| Obsessive compulsive disorder [ICD-11: 6B20; ICD-9: 300.3] | Phase 2 | [1] | ||
| Therapeutic Class |
Antiinfective Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C3H6N2O2
|
|||
| Canonical SMILES |
C1C(C(=O)NO1)N
|
|||
| InChI |
1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
|
|||
| InChIKey |
DYDCUQKUCUHJBH-UWTATZPHSA-N
|
|||
| CAS Number |
CAS 68-41-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10257, 602895, 829389, 841629, 3139717, 7847941, 7885338, 7979010, 8149277, 8153915, 11110913, 11110914, 11110915, 11112194, 11112195, 11335273, 11360512, 11363754, 11366316, 11368878, 11371441, 11374029, 11377040, 11461484, 11467117, 11468237, 11483744, 11486765, 11487900, 11490187, 11492120, 11494674, 12014545, 15170469, 17404815, 24277962, 24858076, 24892907, 24892979, 25622405, 26611680, 26679210, 26719637, 29214856, 29225230, 46386864, 46392863, 46506865, 46507135, 47216632
|
|||
| ChEBI ID |
CHEBI:40009
|
|||
| ADReCS Drug ID | BADD_D00550 | |||
| SuperDrug ATC ID |
J04AB01
|
|||
| SuperDrug CAS ID |
cas=000068417
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. | |||
| REF 2 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
| REF 5 | Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52. | |||
| REF 6 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.